Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma

Molecular markers for predicting or monitoring the efficacy of bevacizumab in patients with metastatic colorectal cancer (mCRC) remain to be identified. We have now measured the serum concentrations of 25 angiogenesis-related molecules with antibody suspension bead array systems for 25 mCRC patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Hayashi, Hidetoshi, Arao, Tokuzo, Matsumoto, Kazuko, Kimura, Hideharu, Togashi, Yosuke, Hirashima, Yoshinori, Horita, Yosuke, Iwasa, Satoru, Okita, Natsuko Tsuda, Honma, Yoshitaka, Takashima, Atsuo, Kato, Ken, Hamaguchi, Tetsuya, Shimada, Yasuhiro, Nakagawa, Kazuhiko, Nishio, Kazuto, Yamada, Yasuhide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4058029/
https://www.ncbi.nlm.nih.gov/pubmed/24809949

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4058029/
https://www.ncbi.nlm.nih.gov/pubmed/24809949

Ejemplares similares